Apyx Medical Corporation
NASDAQ:APYXMedical - Devices
-$0.08 today
- Market cap
- $104.89M
- Beta
- 1.39
- P/E (TTM)
- -19.0
- EPS (TTM)
- -$0.22
Volume 0.19M
Average 0.18M
APYX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Apyx Medical CorporationNASDAQ: APYX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $765K fell 4.9% year over year, ahead of the -25.7% change in trailing-twelve-month research & development. Sequentially, it fell 19.0% from the prior quarter. Over 3 fiscal years it compounded at -9.5% a year.
Context
- Research & development amounted to 6.4% of revenue in FY2025, down 4.2 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -4.9% holds above the trailing-twelve-month pace of -25.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 3.37M USD
- Year-over-year change
- -33.6%
- 4-year CAGR
- -6.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.37M | -33.6% |
| FY2024 | 2024-12-31 | 5.08M | +4.9% |
| FY2023 | 2023-12-31 | 4.84M | +6.6% |
| FY2022 | 2022-12-31 | 4.54M | +5.2% |
| FY2021 | 2021-12-31 | 4.32M | — |
Research & Development vs competitors
How APYX compares with its peers on the latest reported figures
- APYX's LTM Mar 2026 research & development of $3.33M is the 6th highest of the 8 companies compared; the peer median is $12.87M.
- Its year-over-year change of -25.7% is the lowest of 8, against a peer median of -7.8%.
- Research & development amounts to 6.0% of revenue for APYX, versus a peer median of 33.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $20.18M | -5.9% | +14.6% | 27.9% | |
| LTM Mar 2026 | $18.17M | +11.9% | +8.6% | — | |
| LTM Mar 2026 | $13.34M | -7.2% | +1.9% | 38.8% | |
| LTM Mar 2026 | $12.87M | -10.5% | -2.6% | 22573.7% | |
| LTM Mar 2026 | $5.46M | -7.8% | +691.2% | 106.3% | |
| LTM Mar 2026 | $3.33M | -25.7% | -9.5% | 6.0% | |
| LTM Mar 2026 | $3.23M | -9.4% | +6.9% | 4.3% | |
| LTM Mar 2026 | $2.09M | -9.0% | +31.9% | 1.7% | |
| Peer median (excluding APYX) | $12.87M | -7.8% | +8.6% | 33.3% | |
Competitors are the stored peer set for APYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.52M | 44.51M | 52.35M | 48.1M | 52.84M |
| Cost of Revenue | 14.92M | 15.38M | 18.59M | 18.74M | 33.81M |
| Gross Profit | 33.6M | 29.13M | 33.76M | 29.36M | 19.03M |
| Gross Margin | 69.3% | 65.4% | 64.5% | 61.0% | 36.0% |
| Research & Development | 4.32M | 4.54M | 4.84M | 5.08M | 3.37M |
| Selling, General & Admin | 43.73M | 48.15M | 48.87M | 43.13M | 36.12M |
| Operating Expenses | 48.05M | 52.69M | 51.02M | 48.21M | 25.48M |
| Depreciation & Amortization | 903K | 890K | 692K | 599K | 655K |
| EBITDA | (13.91M) | (22.01M) | (18.11M) | (16.8M) | (4.59M) |
| EBITDA Margin | -28.7% | -49.4% | -34.6% | -34.9% | -8.7% |
| Operating Income | (14.45M) | (23.56M) | (17.26M) | (18.85M) | (6.45M) |
| Operating Margin | -29.8% | -52.9% | -33.0% | -39.2% | -12.2% |
| Interest Income | 11K | 157K | 921K | 1.61M | 1.11M |
| Interest Expense | 10K | 15K | 2.48M | 5.91M | 5.59M |
| Other Income / Expenses | (372K) | 651K | (4.02M) | (4.46M) | (4.39M) |
| Income Before Tax | (14.82M) | (22.91M) | (21.28M) | (23.31M) | (10.84M) |
| Pre-Tax Margin | -30.5% | -51.5% | -40.7% | -48.5% | -20.5% |
| Income Tax Expense | 380K | 367K | (2.43M) | 252K | 270K |
| Net Income | (15.17M) | (23.18M) | (18.71M) | (23.46M) | (11.21M) |
| Net Margin | -31.3% | -52.1% | -35.7% | -48.8% | -21.2% |
| EPS (Basic) | (0.44) | (0.67) | (0.54) | (0.66) | (0.27) |
| EPS (Diluted) | (0.44) | (0.67) | (0.54) | (0.66) | (0.27) |
| Weighted Avg Shares | 34.33M | 34.52M | 34.62M | 35.54M | 42.16M |
| Weighted Avg Shares (Diluted) | 34.33M | 34.52M | 34.62M | 35.54M | 42.16M |
Apyx Medical Corporation
NASDAQ:APYX
Intrinsic Alpha fair value
Locked
Current Price
$2.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.